CV risk lingers up to three years for patients who had COVID-19 before vaccine rollout, doctors say
Patients who had COVID-19 prior to the rollout of vaccines have an increased risk of major adverse cardiovascular events for up to three years after…
Tag: Heart disease
‘We’re now in a golden age’: Professor Stephen Nicholls’ big takeaway from the American College of Cardiology conference
Last week, the American College of Cardiology’s Annual Scientific Sessions 2024 was held in Atlanta, Georgia. Thousands of cardiologists and academics were in attendance, including…
Did you miss the American College of Cardiology conference? Watch this 10-min video to get up to speed
The American College of Cardiology’s Annual Scientific Sessions 2024 was held in Atlanta, Georgia, on 6-8 April. More than 12,000 attendees were there to discuss…
‘Set-and-forget’ cholesterol-busting drug now on the PBS
The potent cholesterol-busting drug inclisiran is now subsidised for adults with hypercholesterolaemia who fail to respond to or tolerate statins and ezetimibe. Inclisiran (Leqvio) —…
Time-restricted dieting tied to higher CV mortality in ‘surprise’ findings
Adults who restrict their food intake to eight hours or less per day are almost twice as likely to die from heart disease than those…
Years-long exposure to ADHD medication increases CVD risk: study
Long-term exposure to ADHD medications is associated with an increased risk of CVD, particularly hypertension and arterial disease, Swedish researchers report. Their registry-based study found…
Leading statins equally cardioprotective in head-to-head trial
Rosuvastatin and atorvastatin are equally effective in cutting the risk of death and cardiac events despite greater LDL cholesterol lowering with rosuvastatin, show results from…
Orthostatic hypotension should not deter intensive BP control: study
Orthostatic hypotension should not deter more intensive blood pressure control in adults with hypertension, according to US doctors who say it has no significant impact…
Which antiplatelet monotherapy is best for CAD secondary prevention?
Antiplatelet monotherapy with clopidogrel or ticagrelor may be safer and more effective for secondary prevention of cardiovascular events than aspirin alone, results from a large…
1 in 4 patients die within a year of first HF hospitalisation: study
Globally, one in four patients die within 12 months of their first heart failure-related hospitalisation, according to a study in JACC: Heart Failure. Dr Biykem…
